Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.86 Consensus Target Price from Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has been assigned an average rating of "Buy" from the seven ratings firms that are covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued a report on the stock in the last year is $32.86.

Several research analysts have weighed in on CPRX shares. Stephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price target on the stock. Bank of America reiterated a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. HC Wainwright increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, January 10th. Finally, StockNews.com cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 11th.

Insiders Place Their Bets

In other news, Director Molly Harper sold 17,500 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 over the last ninety days. 11.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. abrdn plc bought a new position in Catalyst Pharmaceuticals in the fourth quarter worth approximately $10,115,000. Spire Wealth Management lifted its holdings in Catalyst Pharmaceuticals by 1,342.9% during the fourth quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after buying an additional 13,429 shares during the period. EMC Capital Management lifted its holdings in Catalyst Pharmaceuticals by 509.7% during the fourth quarter. EMC Capital Management now owns 14,761 shares of the biopharmaceutical company's stock worth $308,000 after buying an additional 12,340 shares during the period. Nilsine Partners LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $700,000. Finally, Pacer Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 5.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock valued at $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 0.2 %

CPRX traded up $0.04 during trading on Friday, hitting $22.55. The company's stock had a trading volume of 653,519 shares, compared to its average volume of 1,275,424. Catalyst Pharmaceuticals has a one year low of $13.12 and a one year high of $24.27. The firm has a market cap of $2.69 billion, a PE ratio of 19.11, a P/E/G ratio of 2.28 and a beta of 0.79. The business's 50 day simple moving average is $21.79 and its 200-day simple moving average is $20.49.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.